Proportions of several types of plasma and urine microparticles are increased in
patients with rheumatoid arthritis with active disease
#MMPMID25639560
Viñuela-Berni V
; Doníz-Padilla L
; Figueroa-Vega N
; Portillo-Salazar H
; Abud-Mendoza C
; Baranda L
; González-Amaro R
Clin Exp Immunol
2015[Jun]; 180
(3
): 442-51
PMID25639560
show ga
We analysed the proportions of different microparticles (MPs) in plasma from
patients with rheumatoid arthritis (RA), and assessed their relationship with
disease activity/therapy and their in-vitro effect on proinflammatory cytokine
release. Blood and urine samples were obtained from 55 patients with RA (24
untreated and 31 under conventional therapy) and 20 healthy subjects. Fourteen
patients with systemic lupus erythematosus (SLE) were also studied. The
proportions of CD3(+) , CD14(+) , CD19(+) , CD41(+) and CD62E(+) MPs were
determined by flow cytometry analysis. The in-vitro effect of plasma MPs on the
release of interleukin (IL)-1, IL-6, IL-17 and tumour necrosis factor (TNF)-? was
also analysed. We detected that the proportions of different types of
annexin-V(+) MPs were enhanced in plasma (CD3(+) , CD14(+) , CD19(+) , CD41(+)
and CD62E(+) MPs) and urine (CD14(+) , CD3(+) and CD19(+) MPs) from RA patients
with high disease activity (DAS28 index?>?5·1). Accordingly, a significant
positive correlation was observed between the levels of MPs and DAS28 score, and
these levels diminished significantly at week 4 of immunosuppressive therapy.
Finally, MPs isolated from patients with high disease activity induced, in vitro,
an enhanced release of IL-1, IL-17 and TNF-?. In SLE, enhanced levels of
different types of plasma MPs were also detected, with a tight correlation with
disease activity. Our data further support that MPs have a relevant role in the
pathogenesis of RA and suggest that the analysis of the proportions of these
microvesicles in plasma could be useful to monitor disease activity and therapy
response in patients with RA.
free
free
free
